Thermo Fisher Scientific Inc. (NYSE:TMO) on Thursday reported fourth-quarter 2025 adjusted earnings of $6.57 per share, beating the street view of $6.45.
Quarterly sales of $12.22 billion increased 7% year-over-year, beating the analyst consensus estimate of $11.95 billion. Organic revenue growth was 3%.
“Throughout the year, we effectively navigated the external environment and leveraged our PPI Business System to enable excellent operational performance. It was also a very active year for capital deployment, as we advanced our strategy and added exciting new capabilities that further strengthen our long-term competitive position,” said Marc Casper, chairman, president, and CEO of Thermo Fisher Scientific.
Life Sciences Solutions sales increased 13.1% to $2.95 billion. Analytical Instruments jumped 1.3% to $2.22 billion.
Specialty Diagnostics revenues reached $1.22 billion, up 5.4%, and Laboratory Products and Biopharma Services sales were up 7.5% to $6.38 billion.
Guidance And Conference Call
In the earnings conference call, Thermo Fisher executive said that the company is entering 2026 from a position of strength and is poised for continued share gains. The growth strategy resonates with customers and supports 2026 objectives.
Thermo Fisher projects 2026 revenue growth between 4% and 6% driven by strategic initiatives and strong operational performance.
The life science giant expects 2026 revenue $46.3-$47.2 billion, with organic growth of 3%-4%.
The company expects 2026 adjusted earnings of $24.22-$24.80 per share, up 6%-8%, compared to the consensus of $24.61, and excludes the pending Clario deal worth $8.875 billion.
The acquisition could add 20 cents to 25 cents to earnings per share in 2026.
TMO Price Action: Thermo Fisher Scientific shares were down 3.20% at $588.57 at the time of publication on Thursday, according to Benzinga Pro data.
Photo via Shutterstock
